Coronary disease & ACSSecondary analysis
Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndrome
- Secondary analysis of the ODYSSEY OUTCOMES randomised trial
- post hoc
Authors' conclusion
In patients with recent ACS on optimized statins without severe hypertriglyceridemia, neither baseline ApoC3 (accounting for ApoB) nor ApoC3 change with alirocumab predicted MACE or death.
Study context
- Population
- Patients with recent acute coronary syndrome (ACS) on optimized statin treatment; fasting triglycerides >400 mg/dL excluded11,176 at M4
- Participants
- 11,956 patients
- Comparison
- Baseline ApoC3 and ApoC3 change on alirocumab vs risk of major adverse cardiovascular events (MACE) or death
- Primary endpoint
- Association of baseline ApoC3 (adjusted for treatment and ApoB) with MACE or death
Primary result
As reported in the abstract
Baseline ApoC3 and MACE or death (adjusted for ApoB)
No association of baseline ApoC3 with MACE
P=0.89
No association of baseline ApoC3 with death
P=0.70
Further findings
MACE
P = 0.0006
Death
P = 0.045
- ApoC3 change with alirocumab · M4
- −10 · median · IQR −27–-5 · mg/L
- ApoC3 change with alirocumab: P<0.0001
Baseline ApoC3 concentration
- Median (Q1, Q3) baseline ApoC3, mg/L
- 85 (65, 113)
ApoC3 change on alirocumab and subsequent MACE or death
- Change in ApoC3 on alirocumab did not predict subsequent MACE or death
Original publication
Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndrome. Eur J Prev Cardiol. Published 8 February 2025. doi:10.1093/eurjpc/zwaf067
Summarised from the published abstract; every number is checked against it